Figure 6
Effect of inhibition of PI3K/mTOR and IKKβ on proliferation and survival of ovarian cancer cells. (a) Effect of BEZ235 (a dual PI3K/mTOR inhibitor) and Bay 65–1942 (an IKKβ inhibitor) on activities of AKT, S6 and 4E-BP1. Immunoblots of p-AKT S473, p-S6 and p-4E-BP1 in FUOV1, NIH:OVCAR3 and IGROV1 ovarian cancer cells after exposure to indicated doses for 6 h. The values below the figures represent relative intensity of the bands normalized to total AKT levels and compared with DMSO-treated cells. (b) Effect of BEZ235 and Bay 65–1942 on CXCL1, CXCL2 and CXCL8 mRNAs in FUOV1, NIH:OVCAR3 and IGROV1 cells. Quantitative RT–PCR analysis was performed in cells treated with indicated inhibitors or DMSO control for 6 h. Data are averages±s.e.m. from three independent experiments. *P<0.05; **P<0.01. (c) Effect of BEZ235 and Bay 65–1942 on cell viability of FUOV1 (top panel), NIH:OVCAR3 (middle panel) and IGROV1 (bottom panel) cells after 72 h treatment. The same concentration of inhibitors as in panels a and b were used. The number of viable cells (unstained by trypan blue) was counted after 72 h treatment. Data are averages±s.e.m. of four independent experiments. n.s., not significant. (d) Effect of BEZ235 and Bay 65–1942 on clonogenic growth of ovarian cancer cells after exposure for 12–14 days. Representative images from two independent experiments are shown.
